Patient P-02670

Synthetic patientMETA-24 · Day 153 · 45–54 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 75 SC-12 recommended — Supportive Compound SC-12
Day 76 Patient accepted — Started SC-12 in the companion
Day 82 GI symptom burden −24% vs expected — Supportive Compound SC-12
Day 88 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

Nutritional resilience-7
GI instability+4
Treatment adherence-4
Inflammatory activity-3
Toxicity-2

What helped?

Supportive Compound SC-12Day 75
Result: symptom burden −24%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
89% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

10 min

improving · +2.6 vs previous 14 d

Sleep duration

Wearable

5.6 h

stable · +0.1 vs previous 14 d

Energy level

Daily log

2.7/10

stable · +0.0 vs previous 14 d

Steps

Wearable

300

improving · +147 vs previous 14 d

GI burden

Companion

59.2/100

worsening · +3.2 vs previous 14 d

Adherence

Companion

45.5 %

stable · +0.0 vs previous 14 d

Sleep quality

Wearable

23.3/100

improving · +3.9 vs previous 14 d

Glucose, CGM daily mean

CGM

141 mg/dL

stable · -0.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 25 from the failing basin, 64 from restoration.

Would help

GI-04 GI Support Protocol
77% improved among 65 similar · onset 8 d · confidence 95%
ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 74%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 74%
More protein
GI -4 next day on high-intake days · n 22

Would not help

Keep histamine low
GI +4.3 next day on high-intake days · n 17
Keep ultra-processed low
GI +3.7 next day on high-intake days · n 20
Keep fat low
GI +3.6 next day on high-intake days · n 13

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+4.3detractor · 95%
Protein
-4supporter · 95%
Ultra-processed food
+3.7detractor · 95%
Dietary fat load
+3.6detractor · 95%
Simple carbohydrates
+2.6detractor · 85%
Insoluble fibre
-1.7no signal · 46%
Alcohol
+0.7no signal · 20%
Caffeine
-0.5no signal · 16%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.6 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable300 steps/day
- WearableShort sleep window
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
Drug metabolism and exposure ↑20
- BloodToxicity index 46

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.3 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 5.7 h
Steps: 897
Resting HR: 73 bpm

Daily log: GI score 59, nutritional resilience 37, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02483	22%	S06	BR-03	no change	64
P-02087	20%	S01	BR-03	no change	40
P-02025	35%	S15	CR-01	improved	61
P-02054	33%	S01	CR-01	improved	57
P-02151	33%	S04	CR-01	improved	49
P-02154	31%	S16	CR-01	improved	57
P-02009	30%	S08	CR-01	improved	64
P-02233	27%	S16	CR-01	improved	66
P-02274	21%	S15	DT-01	improved	50
P-02395	21%	S12	DT-01	improved	57
P-02491	21%	S09	DT-01	no change	65
P-02339	20%	S03	DT-01	improved	50